Historical Valuation
Eledon Pharmaceuticals Inc (ELDN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.14. The fair price of Eledon Pharmaceuticals Inc (ELDN) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.73
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Eledon Pharmaceuticals Inc (ELDN) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of -0.52 , the current P/B ratio is approximately -306.79% higher. Relative to its 5-year average P/B ratio of -0.11, the current P/B ratio is about -1105.20% higher. Eledon Pharmaceuticals Inc (ELDN) has a Forward Free Cash Flow (FCF) yield of approximately -55.23%. Compared to its 3-year average FCF yield of -60.40%, the current FCF yield is approximately -8.57% lower. Relative to its 5-year average FCF yield of -54.84% , the current FCF yield is about 0.72% lower.
P/B
Median3y
-0.52
Median5y
-0.11
FCF Yield
Median3y
-60.40
Median5y
-54.84
Competitors Valuation Multiple
AI Analysis for ELDN
The average P/S ratio for ELDN competitors is 235.25, providing a benchmark for relative valuation. Eledon Pharmaceuticals Inc Corp (ELDN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ELDN
1Y
3Y
5Y
Market capitalization of ELDN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ELDN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ELDN currently overvalued or undervalued?
Eledon Pharmaceuticals Inc (ELDN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.14. The fair price of Eledon Pharmaceuticals Inc (ELDN) is between to according to relative valuation methord.
What is Eledon Pharmaceuticals Inc (ELDN) fair value?
ELDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Eledon Pharmaceuticals Inc (ELDN) is between to according to relative valuation methord.
How does ELDN's valuation metrics compare to the industry average?
The average P/S ratio for ELDN's competitors is 235.25, providing a benchmark for relative valuation. Eledon Pharmaceuticals Inc Corp (ELDN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Eledon Pharmaceuticals Inc (ELDN) as of Jan 10 2026?
As of Jan 10 2026, Eledon Pharmaceuticals Inc (ELDN) has a P/B ratio of 1.07. This indicates that the market values ELDN at 1.07 times its book value.
What is the current FCF Yield for Eledon Pharmaceuticals Inc (ELDN) as of Jan 10 2026?
As of Jan 10 2026, Eledon Pharmaceuticals Inc (ELDN) has a FCF Yield of -55.23%. This means that for every dollar of Eledon Pharmaceuticals Inc’s market capitalization, the company generates -55.23 cents in free cash flow.
What is the current Forward P/E ratio for Eledon Pharmaceuticals Inc (ELDN) as of Jan 10 2026?
As of Jan 10 2026, Eledon Pharmaceuticals Inc (ELDN) has a Forward P/E ratio of -1.69. This means the market is willing to pay $-1.69 for every dollar of Eledon Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Eledon Pharmaceuticals Inc (ELDN) as of Jan 10 2026?
As of Jan 10 2026, Eledon Pharmaceuticals Inc (ELDN) has a Forward P/S ratio of 0.00. This means the market is valuing ELDN at $0.00 for every dollar of expected revenue over the next 12 months.